We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Astellas Pharma Inc. (ALPMY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Astellas Pharma Inc. is one of 998 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ALPMY has gained about 1% so far this year. Meanwhile, stocks in the Medical group have lost about 2.4% on average. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is AtriCure (ATRC - Free Report) . The stock is up 8.1% year-to-date.
For AtriCure, the consensus EPS estimate for the current year has increased 25.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Astellas Pharma Inc. belongs to the Medical - Drugs industry, a group that includes 164 individual companies and currently sits at #71 in the Zacks Industry Rank. On average, this group has gained an average of 3% so far this year, meaning that ALPMY is slightly underperforming its industry in terms of year-to-date returns.
In contrast, AtriCure falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #140. Since the beginning of the year, the industry has moved +5.7%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Astellas Pharma Inc. and AtriCure as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Astellas Pharma Inc. (ALPMY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Astellas Pharma Inc. is one of 998 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ALPMY has gained about 1% so far this year. Meanwhile, stocks in the Medical group have lost about 2.4% on average. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is AtriCure (ATRC - Free Report) . The stock is up 8.1% year-to-date.
For AtriCure, the consensus EPS estimate for the current year has increased 25.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Astellas Pharma Inc. belongs to the Medical - Drugs industry, a group that includes 164 individual companies and currently sits at #71 in the Zacks Industry Rank. On average, this group has gained an average of 3% so far this year, meaning that ALPMY is slightly underperforming its industry in terms of year-to-date returns.
In contrast, AtriCure falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #140. Since the beginning of the year, the industry has moved +5.7%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Astellas Pharma Inc. and AtriCure as they could maintain their solid performance.